Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several interaction-related claims are partially supported (CYP3A4 inhibition and increased atorvastatin plasma concentrations; contraindication/precaution context for muscle/liver/bleeding is broadly consistent with labeled adverse reactions and warnings). However, multiple quantitative and absolutist statements (e.g., “up to 50%,” “no safe amount,” “small amounts,” and specific frequency/severity comparisons) are not supported by the provided label excerpts, and some interaction examples (e.g., felodipine, midazolam) are not supported within the supplied grapefruit/CYP3A4 interaction text.
Category Scores
Accurate Statements
Grapefruit juice contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Label 7.2 Grapefruit Juice: "Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day)."
CYP3A4 is involved in the metabolism of atorvastatin/LIPITOR.
Label 12.3 Pharmacokinetics: "LIPITOR is metabolized by CYP3A4..."
The risk of myopathy/muscle-related adverse effects is increased with certain interacting drugs and in general with statins; myopathy/rhabdomyolysis are labeled warnings.
Label 5.1 Skeletal Muscle: "Atorvastatin, like other statins, occasionally causes myopathy..." and "Rare cases of rhabdomyolysis..."; Label 7 Drug Interactions: "The risk of myopathy during treatment with statins is increased with... cyclosporine, or strong CYP 3A4 inhibitors..."
Grapefruit juice can increase atorvastatin plasma concentrations, particularly with excessive consumption (>1.2 liters/day).
Label 7.2 Grapefruit Juice: "especially with excessive grapefruit juice consumption (>1.2 liters per day)."
In patients taking cyclosporine, LIPITOR dose should be limited to 10 mg once daily.
Label 7.3 Cyclosporine: "...dose of LIPITOR should not exceed 10 mg..."
Unsupported Statements
CYP3A4 is responsible for metabolizing many medications, including Lipitor (atorvastatin).
The provided excerpts state LIPITOR is metabolized by CYP3A4 but do not claim CYP3A4 metabolizes many medications.
By blocking CYP3A4, grapefruit juice can increase Lipitor levels in the bloodstream.
The label supports increased plasma concentrations via CYP3A4 inhibition, but the AI wording frames it as a direct causal mechanism (“by blocking”) rather than the label’s phrasing; still largely consistent, but mechanism phrasing is not directly stated in those terms.
Grapefruit juice can increase the bioavailability of Lipitor by up to 50%.
No quantitative increase (e.g., 50%) is provided in the supplied label excerpts.
Consuming grapefruit juice with Lipitor results in significantly higher levels of atorvastatin in the bloodstream compared to taking the medication alone.
The label excerpt states plasma concentrations can increase, especially with excessive consumption, but does not provide the specific “significantly higher” comparative phrasing in the supplied text.
Consuming grapefruit juice with Lipitor can lead to adverse effects such as muscle pain.
The label excerpt includes myopathy/rhabdomyolysis and myalgia as a common adverse reaction leading to discontinuation, but it does not explicitly link grapefruit juice co-consumption to muscle pain.
Consuming grapefruit juice with Lipitor can lead to adverse effects such as liver damage.
Liver dysfunction/hepatic enzyme elevations are labeled adverse effects/warnings, but the provided excerpts do not explicitly link grapefruit juice co-consumption to liver damage.
Consuming grapefruit juice with Lipitor can increase the risk of bleeding.
The label excerpt includes hemorrhagic stroke risk in a specific 80 mg trial context (SPARCL), but the provided grapefruit interaction excerpts do not state grapefruit juice increases bleeding risk.
The FDA has issued warnings about the potential risks of combining grapefruit juice with Lipitor due to increased risk of adverse effects.
The supplied excerpts are from the product label and do not mention FDA-issued warnings.
Patients who consumed grapefruit juice with Lipitor experienced more frequent and severe adverse effects compared to those who took the medication alone.
No such comparative patient-level frequency/severity data for grapefruit co-consumption is included in the provided excerpts.
There is no safe amount of grapefruit juice that can be consumed with Lipitor.
The label excerpt specifies increased risk especially with excessive grapefruit consumption (>1.2 liters/day), which does not support an absolute “no safe amount.”
Grapefruit juice can still increase Lipitor levels even with small amounts.
The label excerpt specifically emphasizes excessive consumption (>1.2 liters/day); the provided excerpts do not state effects with “small amounts.”
Lipitor with grapefruit juice is not recommended even if the patient is not experiencing any adverse effects.
The provided label excerpts do not state an explicit “not recommended” directive regarding grapefruit juice irrespective of symptoms.
It is not recommended to take Lipitor with other medications that interact with grapefruit juice, such as cyclosporine.
The label supports cyclosporine interaction dose limitation, but does not frame it as “other medications that interact with grapefruit juice.”
It is not recommended to take Lipitor with other medications that interact with grapefruit juice, such as felodipine.
Felodipine is not mentioned in the provided label excerpts.
It is not recommended to take Lipitor with other medications that interact with grapefruit juice, such as midazolam.
Midazolam is not mentioned in the provided label excerpts.
Contradictions
Important Omissions
Grapefruit juice interaction is described as especially associated with excessive consumption (>1.2 liters per day), which the AI response does not include.
Importance:
Moderate
For cyclosporine, the label provides a specific dosing limitation (limit atorvastatin to 10 mg once daily when co-administered if necessary). The AI response does not mention this dosing limitation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overgeneralized and unsupported absolutes (“no safe amount,” “still even with small amounts”) and unsupported quantitative/clinical-comparison claims may lead to unnecessarily rigid avoidance or misinterpretation of risk, though the core direction that grapefruit can increase atorvastatin plasma concentrations via CYP3A4 inhibition is supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts, including quantitative (“up to 50%”), absolute safety (“no safe amount”), and specific comparators/data (frequency/severity vs control). Some drug examples (felodipine, midazolam) are not present in the supplied label.
Suggested Improvement
Limit statements to label-supported points: grapefruit contains components that inhibit CYP3A4 and can increase atorvastatin plasma concentrations especially with excessive (>1.2 L/day) intake; avoid unsupported quantitative figures and absolutes; cite label-supported guidance for interacting drugs (e.g., cyclosporine dose limit to 10 mg).